Headache Treatment in Active Multiple Sclerosis
For headaches in adults with active MS, start with NSAIDs (ibuprofen 400mg or naproxen) or acetaminophen (1000mg), and if inadequate response, add a triptan to the NSAID or acetaminophen. If these fail, consider anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) or gepants (rimegepant, ubrogepant), which show emerging evidence of safety and efficacy specifically in MS patients 1, 2.
Treatment Algorithm
First-Line Acute Treatment
- NSAIDs: Ibuprofen 400mg, naproxen, or diclofenac 3, 4
- Acetaminophen: 1000mg if NSAIDs contraindicated 4
- Ensure adequate dosing before escalating therapy
Second-Line: Combination Therapy
- Add a triptan to NSAID for moderate-to-severe headaches not responding to NSAIDs alone 4
- Add a triptan to acetaminophen if NSAIDs are contraindicated 4
- Triptans available: sumatriptan, rizatriptan, eletriptan, zolmitriptan, almotriptan, naratriptan, frovatriptan 4
- Start treatment as soon as headache begins for maximum efficacy 4
Third-Line: MS-Specific Considerations
If combination therapy fails or is not tolerated:
- Anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) are particularly attractive in MS because they have minimal drug-drug interactions with disease-modifying therapies 1, 5
- Gepants (rimegepant, ubrogepant, zavegepant) for acute treatment 4
- Recent evidence shows anti-CGRP therapies reduced monthly headache days from 19.87 to 11.40 in MS patients without affecting MS disease activity 1
Fourth-Line
- Lasmiditan (ditan class) only if all other options fail 4
Critical MS-Specific Considerations
Medication Selection Cautions
- Avoid certain preventive medications that can worsen MS cognitive symptoms 5, 6
- Carefully select preventive agents based on side effect profiles that may overlap with MS symptoms 7, 6
- Anti-CGRP therapies appear safe with concurrent MS disease-modifying therapies, with no worsening of MS activity, EDSS scores, or MRI findings 1, 2
Predictors of Response in MS Patients
- Higher baseline headache frequency predicts better response to anti-CGRP therapies 1
- Longer MS disease duration predicts poorer response (OR 1.43,95% CI 1.06-1.92) 1
- Response rate to anti-CGRP therapies in MS patients: 53.7% at last follow-up 1
Headache Types in MS
- Tension-type headache (TTH) is significantly more common in MS (24.0%) than controls (16.7%) 8
- Migraine prevalence in MS is similar to general population (16.0% vs 17.0%) 8
- Secondary headaches from MS relapses are common and often migraine-like, improving with MS-specific therapy 7
- Headaches from disease-modifying drugs (especially interferon-beta) are frequent 7
Important Warnings
Medications to AVOID
- Do not use opioids or butalbital for acute episodic migraine 4
- These worsen outcomes and increase risk of medication overuse headache
Medication Overuse Headache Thresholds
- NSAIDs: ≥15 days per month 4
- Triptans: ≥10 days per month 4
- Monitor usage carefully to prevent transformation to chronic daily headache
Additional Acute Management
- For severe nausea/vomiting: use non-oral triptan formulations plus antiemetic 4
- Consider physical therapy or aerobic exercise as adjunctive management 3
When to Add Prevention
If episodic headaches occur frequently or acute treatment provides inadequate response, initiate preventive therapy with options including topiramate, valproate, angiotensin-receptor blockers, lisinopril, memantine, or anti-CGRP monoclonal antibodies 3. The anti-CGRP antibodies are particularly advantageous in MS due to limited drug interactions with disease-modifying therapies 1, 5.